Starpharma Holdings Ltd. engages in the research and development of dendrimer products for pharmaceutical, life science and other applications. The company is headquartered in Melbourne, Victoria. Its programs for respiratory viruses, Dendrimer Enhanced Product (DEP) drug delivery and VivaGel. The Company’s products include VIRALEZE, VivaGel condom and VivaGel BV. VIRALEZE product is applied to the nasal cavity where respiratory viruses that cause colds, flu, and more severe respiratory illness, attach and start to multiply. VIRALEZE also provides a moisturizing and protective barrier in the nose and contains SPL7013. VivaGel is an agent applied to a range of marketed women’s health and sexual wellness products. VivaGel BV is a novel therapy for bacterial vaginosis (BV), the vaginal infection. VivaGelBV is available for sale under the brand names Betafem BV Gel (UK), Betadine BV (Europe), Betadine BV Gel (Asia) and Fleurstat BVgel (Australia & New Zealand) and licensed in over 160 countries.
Starpharma Holdings (ASX: SPL)
- Home
- Starpharma Holdings (ASX: SPL)
Here are the latest articles on Starpharma Holdings (ASX: SPL)
Firebrick completes recruitment for Phase 3 nasal spray trial, seeks to finally get TGA approval
August 9, 2023
Can you spray away the common cold? Pharma company Firebrick Pharma (ASX: FRE) says yes. After completing two clinical trials, the Company has entered Phase 3 trials for its Nasodine Nasal Spray, which has enrolled 500 patients to trial the product. The primary objective of the study is to assess the effectiveness of Nasodine compared
Starpharma gains regulatory approval in Malaysia for nasal spray to build momentum in Asia
June 5, 2023
Biopharmaceutical company Starpharma (ASX: SPL) has received regulatory approval for its antiviral nasal spray product, VIRALEZE, in Malaysia. This milestone achievement grants Starpharma and its commercial partners the opportunity to market and sell the innovative product in Malaysia, a country with a population exceeding 33 million. VIRALEZE has garnered significant recognition in Asia following successful
Starpharma’s DEP shows promising results on prostate cancer patients
September 12, 2022
Offering some relief for people suffering from prostate cancer, Starpharma (ASX: SPL) might be on the verge of a breakthrough as it announced that its drug DEP® cabazitaxel has shown promising anti-tumour activity data at the European Society of Medical Oncology (ESMO) Congress in Paris, France. The new data from its phase 2 trial reveals
Why reinvent the wheel? Starpharma is using their tech to improve existing drugs
December 7, 2021
We live in the age of optimisation. Constantly asking questions like how can we be more efficient? How can we streamline processes? How can we enhance ourselves with the resources available? The pharmaceutical scene is no different, seeking to optimise drugs in any way possible to produce better patient outcomes. Biopharmaceutical company Starpharma (ASX: SPL)
Recent Articles
